FDA Urges Caution For Users Of Novartis' MS Drug
The U.S. Food and Drug Administration said Monday that a safety review of Novartis AG's Gilenya found no solid evidence that the multiple sclerosis drug caused a patient's death last year,...To view the full article, register now.
Already a subscriber? Click here to view full article